Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience

International Journal of Infectious Diseases

Volumn 67, Issue , 2018, Pages 114-117

  del Campo, José A ^a,b   Parra Sánchez, Manuel ^a   Figueruela, Blanca ^a   García Rey, Silvia ^a   Quer, Josep ^b,c   Gregori, Josep ^b,c,d   Bernal, Samuel ^a   Grande, Lourdes ^a   Palomares, José C ^a   Romero Gómez, Manuel ^b,e  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d Roche Diagnostics SL Diabetes Care   (Spain)

^e Instituto de Biomedicina de Sevilla   (Spain)

Author keywords

Deep sequencing; Direct acting antivirals; HCV; Mixed infection; NGS

Indexed keywords

ANTIVIRUS AGENT; DIRECT ACTING ANTIVIRAL AGENT; UNCLASSIFIED DRUG; VIRUS RNA; VIRAL PROTEIN;

ARTICLE; DIAGNOSTIC ACCURACY; DRUG TREATMENT FAILURE; GENOTYPING TECHNIQUE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HEPATITIS C VIRUS SUBTYPE 3A; HEPATITIS C VIRUS SUBTYPE 4A; HEPATITIS C VIRUS SUBTYPE 4D; HEPATITIS C VIRUS SUBTYPE 4F; HUMAN; MAJOR CLINICAL STUDY; MIXED INFECTION; NESTED POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; VIRUS LOAD; ADULT; CLASSIFICATION; DNA SEQUENCE; FEMALE; GENETICS; GENOTYPE; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; VIROLOGY;

ADULT; COINFECTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85040374472     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2017.12.016     Document Type: Article

References (22)

1. Avó, A.P., Água-Doce, I., Andrade, A., Pádua, E., Hepatitis C virus subtyping based on sequencing of the C/E1 and NS5B genomic regions in comparison to a commercially available line probe assay. J Med Virol 85 (2013), 815–822.
2. Bagaglio, S., Andolina, A., Merli, M., Uberti-Foppa, C., Morsica, G., Frequency of natural resistance within NS5a replication complex domain in hepatitis C genotypes 1a, 1b: possible implication of subtype-specific resistance selection in multiple direct acting antivirals drugs combination treatment. Viruses, 8, 2016, 91.
3. Chevaliez, S., Bouvier-Alias, M., Brillet, R., Pawlotsky, J.-M., Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. Lindenbach, B., (eds.) PLoS One, 4, 2009, e8209.
4. European Association for Study of Liver, EASL recommendations on treatment of hepatitis C 2015. J Hepatol 63 (2015), 199–236.
5. Farci, P., Purcell, R.H., Clinical significance of hepatitis C virus genotypes and quasispecies. Semin Liver Dis 20 (2000), 103–126.
6. González, V., Gomes-Fernandes, M., Bascuñana, E., et al. Accuracy of a commercially available assay for HCV genotyping and subtyping in the clinical practice. J Clin Virol 58 (2013), 249–253.
7. Legrand-Abravanel, F., Colson, P., Leguillou-Guillemette, H., et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J Med Virol 81 (2009), 2029–2035.
8. McNaughton, A.L., Thomson, E.C., Templeton, K., Gunson, R.N., Leitch, E.C.M., Mixed genotype hepatitis C infections and implications for treatment. Hepatology, 59, 2014, 1209.
9. Nieto-Aponte, L., Quer, J., Ruiz-Ripa, A., et al. Assessment of a novel automatic real-time PCR assay on the Cobas 4800 analyzer as a screening platform for hepatitis C virus genotyping in clinical practice: comparison with massive sequencing. J Clin Microbiol 55 (2017), 504–509.
10. Patiño-Galindo, J.Á., Salvatierra, K., González-Candelas, F., López-Labrador, F.X., Comprehensive screening for naturally occurring hepatitis C virus resistance to direct-acting antivirals in the NS3, NS5A, and NS5B genes in worldwide isolates of viral genotypes 1 to 6. Antimicrob Agents Chemother 60 (2016), 2402–2416.
11. Pham, S.T., Bull, R.A., Bennett, J.M., et al. Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology 52 (2010), 1564–1572.
12. Poordad, F., Hezode, C., Trinh, R., et al. ABT-450/r–ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370 (2014), 1973–1982.
13. Poveda, E., Wyles, D.L., Mena, Á., Pedreira, J.D., Castro-Iglesias, Á., Cachay, E., Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res 108 (2014), 181–191.
14. Quer, J., Gregori, J., Rodríguez-Frias, F., et al. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. Tang, Y.-W., (eds.) J Clin Microbiol, 53, 2015, 219–226.
15. Quer, J., Rodríguez-Frias, F., Gregori, J., et al. Deep sequencing in the management of hepatitis virus infections. Virus Res 239 (2017), 115–125 S0168-1702(16)30456-7.
16. Simmonds, P., Bukh, J., Combet, C., et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42 (2005), 962–973.
17. Smith, D.B., Bukh, J., Kuiken, C., et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59 (2014), 318–327.
18. Tarr, A.W., Khera, T., Hueging, K., et al. Genetic diversity underlying the envelope glycoproteins of hepatitis C Virus: structural and functional consequences and the implications for vaccine design. Viruses 7 (2015), 3995–4046.
19. Thomson, E.C., Fleming, V.M., Main, J., et al. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 60 (2011), 837–845.
20. Tong, Y.-Q., Liu, B., Liu, H., et al. Accurate genotyping of hepatitis C virus through nucleotide sequencing and identification of new HCV subtypes in China population. Clin Microbiol Infect, 21, 2015 874.e9-874.e21.
21. Wendt, A., Adhoute, X., Castellani, P., et al. Chronic hepatitis C: future treatment. Clin Pharmacol 6 (2014), 1–17.
22. Zeuzem, S., Mizokami, M., Pianko, S., et al. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol 66 (2017), 910–918.